Novel Platinum-boron Complexes with Potential Anticancer Activity PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Novel Platinum-boron Complexes with Potential Anticancer Activity PDF full book. Access full book title Novel Platinum-boron Complexes with Potential Anticancer Activity by Hanni Adel Darwish. Download full books in PDF and EPUB format.
Author: Hanni Adel Darwish
Publisher:
ISBN:
Category : Antineoplastic agents
Languages : en
Pages : 96
Get Book Here
Book Description
Author: Hanni Adel Darwish
Publisher:
ISBN:
Category : Antineoplastic agents
Languages : en
Pages : 96
Get Book Here
Book Description
Author: Liliya G. Nikolcheva
Publisher:
ISBN:
Category : Platinum compounds
Languages : en
Pages : 102
Get Book Here
Book Description
Author: Justin Jeff Wilson
Publisher:
ISBN:
Category :
Languages : en
Pages : 345
Get Book Here
Book Description
(cont'd) Chapter 6. Synthesis, Characterization, and Cytotoxicity of Platinum(IV) Dicarbamate Complexes The reaction of cis,cis,trans-[Pt(NH3)2Cl2(OH)2] with alkyl and aryl isocyanates (RNCO) in DMF afforded dicarbamate complexes of the general formula cis,cis,trans- [Pt(NH 3)2Cl 2(O 2CNHR)2]. The resulting complexes were fully characterized by X-ray crystallography, multinuclear NMR spectroscopy, and cyclic voltammetry. The anticancer activities of these complexes were assessed in human lung cancer (A549) and human lung fibroblast (MRC-5) cell lines. Although no clear structure-activity relationships could be delineated, the complexes exhibited activity on the same order of magnitude as that of the clinically established drug cisplatin. Therefore, the reaction of cis,cis,trans-[Pt(NH3)2Cl 2(OH)2] with isocyanates provides a powerful new synthetic pathway to functionalize platinum(IV) anticancer agents. Appendix A. Aqueous Electrochemistry of a Platinum(IV) Prodrug Electrochemical studies of cis,cis,trans-[Pt(NH3)2Cl2(OAc) 2] in aqueous media were carried out. Cyclic voltammetry in pH 7.4 phosphate-buffered saline with glassy carbon and Pt disk working electrodes gave substantially different peak potentials for the irreversible reduction feature. Under these conditions, the glassy carbon electrode was plated with platinum metal derived from the platinum(IV) complex, as determined by cyclic voltammetry and chronoamperometry experiments. The bulk electrolysis of cis,cis,trans-[Pt(NH3)2Cl2(OAc)2] in aqueous solution at a carbon felt working electrode was investigated by 1H NMR spectroscopy. These studies indicate ligand loss upon reduction from both axial and equatorial sites of the platinum(IV) complex. Appendix B. Targeting the Mitochondria with Platinum Anticancer Agents using Mitochondria-Penetrating Peptides Early results of a collaborative effort with the lab of Professor Shana 0. Kelley at the University of Toronto to deliver platinum anticancer agents to the mitochondria are presented. Succinylacetone (Hsuccac) was used as a leaving group ligand for a cis-diammineplatinum(II) complex. The complex [Pt(succac)(NH 3)2](NO3), which contains a terminal, uncoordinated carboxylic acid functional group, was prepared and fully characterized. This complex was conjugated to a mitochondria-penetrating peptide (MPP) using standard solid-phase coupling chemistry. The anticancer activity of the Pt-MPP construct was tested in both wild-type and cisplatin-resistant ovarian cancer cell lines, A2780 and A2780CP70. Although less potent than cisplatin, the construct is equally toxic to both cell lines, thereby indicating that targeting the mitochondria provides a viable strategy for circumventing resistance to platinum drugs. Appendix C. Synthesis and Characterization of Several Novel Platinum Complexes Throughout the course of this thesis work, several platinum complexes were synthesized and characterized, but ultimately not fully pursued as potential anticancer agents. These species include platinum compounds with dichloroacetate, 2,2'-bis(1- methylimidazolyl)phenylmethoxymethane (BIPhMe), nitrogen mustard-containing, and nitroimidazole-derivatized ligands. The syntheses and characterization of these compounds are reported. Crystal structures are described for several of them.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages :
Get Book Here
Book Description
Author: Brittany Miles
Publisher:
ISBN:
Category : Cancer
Languages : en
Pages : 102
Get Book Here
Book Description
Author: Yan Ma
Publisher:
ISBN:
Category : Organopalladium compounds
Languages : en
Pages : 118
Get Book Here
Book Description
Author: Jennifer Lynne Horton
Publisher:
ISBN:
Category : Cancer
Languages : en
Pages : 140
Get Book Here
Book Description
Author: Xiao Liu
Publisher:
ISBN:
Category :
Languages : de
Pages : 0
Get Book Here
Book Description
In recent decades, Pt(II)-based chemotherapy drugs, such as cisplatin, oxaliplatin, and carboplatin, have been among the most effective drugs for cancer treatment. They have been widely used in various malignant solid tumors, including lung cancer, colorectal cancer, testicular cancer, ovarian cancer, bladder cancer, and head and neck cancer. Despite the well-documented success, there are still challenges to be addressed, such as intrinsic and acquired resistance, as well as side effects including nephrotoxicity, neurotoxicity, and cardiotoxicity. To maximize their effectiveness and broaden their therapeutic potential, researchers have devoted a lot of effort to exploring new derivatives and combination therapies. Among these efforts, Pt(IV) complexes, acting as prodrugs that can be activated to release active Pt(II) species, have exhibited great promise. Tremendous efforts have been devoted to exploring new synthesis approaches, elucidating structure-activity relationships, and designing novel Pt(IV) complexes that incorporate biologically active or therapeutically effective ligands. The aim is to enhance drug efficiency through increasing cytotoxicity, achieving more targeted delivery, enabling oral availability, and circumventing drug resistance, among other goals.The specific areas of focus include i) Analysis of the reduction capacity, including the determination of reduction potential (Ep) and the assessment of reduction in the presence of small reducing agents like ascorbic acid; ii) lipophilicity versus cellular accumulation; iii) stability study; iv) binding with 9-methylguanine (a simple DNA model); v) biological activities including cytotoxicity, ROS generation, cellular accumulation, COX inhibition, apoptosis induction, and more.
Author: Michael Steven Datt
Publisher:
ISBN:
Category : Chemotherapy
Languages : en
Pages : 576
Get Book Here
Book Description
Author: Jolanda Myburgh
Publisher:
ISBN:
Category : Antineoplastic agents
Languages : en
Pages : 288
Get Book Here
Book Description
